Here you will find a curated selection of top industry content related to Cellular, Acellular, and Matrix-like Products (CAMPS)

.

The updated Local Coverage Determination (LCD) for CAMPs, effective 12 February 2025, introduces expanded application limits, extended therapy duration, and clarified care standards for diabetic foot and venous leg ulcers. Reflecting advocacy efforts, these changes enhance clinical flexibility and align with standard practices, though some limitations remain. The update represents progress towards improved wound care delivery.

READ IT HERE

.

The American College of Clinical Wound Specialists is excited to announce its collaboration with the upcoming AVLS 38th Annual Congress, the largest vein and lymphatic medical conference in the United States. This four-day educational event will take place at the Sheraton Grand Chicago Riverwalk from October 10-13, 2024.

READ IT HERE



Medicare's proposed LCD for cellular tissue products (CTPs)/cellular, acellular, and matrix-like products (CAMPs) for Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs) hinders patient access to essential treatment options, encourages unsafe, outdated practices and negatively impacts healing outcomes. Please join us in voicing your support to ensure patients will continue to have access to these essential wound care products.

READ IT HERE



PRESS RELEASE – Open letter to the Medicare Administrative Contractors (MACs) expressing concerns over the potential unfavorable impact on patient care resulting from their proposed draft cellular, acellular, and matrix-like products (CAMPs) local coverage determinations (LCDs).

READ IT HERE